SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 155 filers reported holding SAGE THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 1.15 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,982,411 | +93.4% | 42,161 | +72.6% | 0.00% | +100.0% |
| Q1 2023 | $1,024,999 | +78.6% | 24,428 | +62.3% | 0.00% | 0.0% |
| Q4 2022 | $573,969 | -47.0% | 15,049 | -45.5% | 0.00% | 0.0% |
| Q3 2022 | $1,082,000 | +438.3% | 27,632 | +343.9% | 0.00% | – |
| Q2 2022 | $201,000 | -56.8% | 6,225 | -43.0% | 0.00% | – |
| Q4 2021 | $465,000 | +13.4% | 10,928 | +18.2% | 0.00% | – |
| Q3 2021 | $410,000 | +5.9% | 9,245 | +35.6% | 0.00% | – |
| Q2 2021 | $387,000 | -99.2% | 6,819 | -99.0% | 0.00% | -100.0% |
| Q1 2021 | $51,572,000 | -18.8% | 689,004 | -6.1% | 0.05% | -25.4% |
| Q4 2020 | $63,490,000 | -3.5% | 733,897 | -31.8% | 0.07% | -15.5% |
| Q3 2020 | $65,810,000 | +61.3% | 1,076,737 | +9.7% | 0.08% | +52.7% |
| Q2 2020 | $40,794,000 | -35.2% | 981,106 | -55.3% | 0.06% | +3.8% |
| Q1 2020 | $62,976,000 | +12.6% | 2,192,716 | +183.1% | 0.05% | -22.1% |
| Q4 2019 | $55,917,000 | -31.6% | 774,587 | +32.9% | 0.07% | -35.2% |
| Q3 2019 | $81,769,000 | -6.4% | 582,858 | +22.2% | 0.10% | -40.3% |
| Q2 2019 | $87,314,000 | +26.4% | 476,891 | +9.8% | 0.18% | +12.1% |
| Q1 2019 | $69,063,000 | +55.5% | 434,221 | -6.3% | 0.16% | +41.4% |
| Q4 2018 | $44,403,000 | -25.3% | 463,541 | +10.2% | 0.11% | -9.8% |
| Q3 2018 | $59,429,000 | -20.2% | 420,735 | -11.5% | 0.12% | -22.2% |
| Q2 2018 | $74,456,000 | +6.3% | 475,665 | +9.4% | 0.16% | +3.3% |
| Q1 2018 | $70,035,000 | +50.8% | 434,815 | +54.2% | 0.15% | +56.1% |
| Q4 2017 | $46,437,000 | +124.9% | 281,930 | -14.9% | 0.10% | +113.0% |
| Q3 2017 | $20,647,000 | -41.8% | 331,405 | -25.6% | 0.05% | -44.6% |
| Q2 2017 | $35,479,000 | +1.8% | 445,485 | -9.2% | 0.08% | 0.0% |
| Q1 2017 | $34,853,000 | +44.1% | 490,415 | +3.5% | 0.08% | +36.1% |
| Q4 2016 | $24,195,000 | +4.8% | 473,838 | -5.5% | 0.06% | -6.2% |
| Q3 2016 | $23,097,000 | – | 501,558 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |